Literature DB >> 32856853

Urine Neutrophil Gelatinase-Associated Lipocalin a Possible Diagnostic Marker for Egyptian Hepatocellular Carcinoma Patients.

Eman Abdelsameea1, Ali Nada1, Nabil Omar1, Saleh M Saleh1, Mary Naguib2, Hosam El-Din M El-Ezawy3, Lamiaa Bakry1, Maha Elsabaawy1.   

Abstract

BACKGROUND: Most effective method for reducing mortality from hepatocellular carcinoma (HCC) is early diagnosis. Despite its lack of adequate sensitivity, ultrasound is considered fundamental for HCC screening. AIM: to evaluate urinary neutrophil gelatinase-associated lipocalin (NGAL) as non-invasive marker for HCC diagnosis in Egyptian patients.
METHODS: One hundred and twenty patients were divided into three groups (40 patients each): patients with chronic viral hepatitis (HCV or HBV), cirrhotic patients and HCC patients and 40 healthy age and gender matched subjects were enrolled as control group. After clinical assessments, urinary NGAL was measured by enzyme-linked immunosorbent assay.
RESULTS: Our results revealed that median level of urinary NGAL was 290, 834, 1090 and 1925 pg/ml in control, chronic hepatitis, cirrhotic and HCC groups respectively among studied groups (p<0.001). Receiver operating characteristics (ROC) analysis showed that urinary NGAL cutoff value of 1255 ng/ml could discriminate between HCC and cirrhosis. The area under curve (AUC) was 0.95 with 90% sensitivity, 87.5% specificity (p-value <0.001). In HCC group, urine NGAL level didn`t show significant correlation with Child Pugh score, MELD score or Barcelona Clinic Liver Cancer (BCLC) stage.
CONCLUSION: Urinary NGAL could be a simple, non-invasive test for diagnosis of HCC in chronic liver disease patients.<br />.

Entities:  

Keywords:  Liver Cirrhosis; hepatocellular carcinoma (HCC); urinary neutrophil gelatinase-associated lipocalin (NGAL)

Mesh:

Substances:

Year:  2020        PMID: 32856853      PMCID: PMC7771944          DOI: 10.31557/APJCP.2020.21.8.2259

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  17 in total

Review 1.  Hepatocellular carcinoma: Where are we?

Authors:  Roberto Mazzanti; Umberto Arena; Renato Tassi
Journal:  World J Exp Med       Date:  2016-02-20

Review 2.  Lipocalin-2 and iron trafficking in the tumor microenvironment.

Authors:  Michaela Jung; Christina Mertens; Rebekka Bauer; Claudia Rehwald; Bernhard Brüne
Journal:  Pharmacol Res       Date:  2017-03-23       Impact factor: 7.658

3.  Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis.

Authors:  X Ariza; I Graupera; M Coll; E Solà; R Barreto; E García; R Moreira; C Elia; M Morales-Ruiz; M Llopis; P Huelin; C Solé; N Fabrellas; E Weiss; F Nevens; A Gerbes; J Trebicka; F Saliba; C Fondevila; V Hernández-Gea; J Fernández; M Bernardi; V Arroyo; W Jiménez; C Deulofeu; M Pavesi; P Angeli; R Jalan; R Moreau; P Sancho-Bru; P Ginès
Journal:  J Hepatol       Date:  2016-03-14       Impact factor: 25.083

4.  The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL.

Authors:  L Yan; N Borregaard; L Kjeldsen; M A Moses
Journal:  J Biol Chem       Date:  2001-08-02       Impact factor: 5.157

Review 5.  Neutrophil gelatinase-associated lipocalin: pathophysiology and clinical applications.

Authors:  E Singer; L Markó; N Paragas; J Barasch; D Dragun; D N Müller; K Budde; K M Schmidt-Ott
Journal:  Acta Physiol (Oxf)       Date:  2013-02-04       Impact factor: 6.311

6.  Protective effects of lipocalin-2 (LCN2) in acute liver injury suggest a novel function in liver homeostasis.

Authors:  Erawan Borkham-Kamphorst; Eddy van de Leur; Henning W Zimmermann; Karlin Raja Karlmark; Lidia Tihaa; Ute Haas; Frank Tacke; Thorsten Berger; Tak W Mak; Ralf Weiskirchen
Journal:  Biochim Biophys Acta       Date:  2013-01-31

7.  Prevalence of hepatocellular carcinoma in chronic hepatitis C patients in Mid Delta, Egypt: A single center study.

Authors:  Dina H Ziada; Sherif El Sadany; Hanan Soliman; Sherief Abd-Elsalam; Marwa Salama; Nehad Hawash; Amal Selim; Manal Hamisa; Hala M Elsabagh
Journal:  J Egypt Natl Canc Inst       Date:  2016-07-01

8.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

9.  Analysis of a urinary biomarker panel for clinical outcomes assessment in cirrhosis.

Authors:  Xavier Ariza; Elsa Solà; Chiara Elia; Rogelio Barreto; Rebeca Moreira; Manuel Morales-Ruiz; Isabel Graupera; Ezequiel Rodríguez; Patricia Huelin; Cristina Solé; Javier Fernández; Wladimiro Jiménez; Vicente Arroyo; Pere Ginès
Journal:  PLoS One       Date:  2015-06-04       Impact factor: 3.240

Review 10.  Lipocalin 2: a potential therapeutic target for breast cancer metastasis.

Authors:  Chenxia Hu; Ke Yang; Mengjie Li; Weiping Huang; Fengxue Zhang; Hongqi Wang
Journal:  Onco Targets Ther       Date:  2018-11-13       Impact factor: 4.147

View more
  2 in total

Review 1.  A Scoping Review on Lipocalin-2 and Its Role in Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma.

Authors:  Marinela Krizanac; Paola Berenice Mass Sanchez; Ralf Weiskirchen; Anastasia Asimakopoulos
Journal:  Int J Mol Sci       Date:  2021-03-11       Impact factor: 5.923

2.  Bioinformatic analysis of the LCN2-SLC22A17-MMP9 network in cancer: The role of DNA methylation in the modulation of tumor microenvironment.

Authors:  Saverio Candido; Barbara Tomasello; Alessandro Lavoro; Luca Falzone; Giuseppe Gattuso; Angela Russo; Sabrina Paratore; James A McCubrey; Massimo Libra
Journal:  Front Cell Dev Biol       Date:  2022-09-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.